Valuation: PolyPid Ltd.

Market Cap 99.9M 87.62M 80.89M 74.75M 142M 9.57B 145M 972M 378M 4.68B 375M 367M 16.25B P/E 2026 *
-3.65x
P/E 2027 * -4.15x
Enterprise Value 99.9M 87.62M 80.89M 74.75M 142M 9.57B 145M 972M 378M 4.68B 375M 367M 16.25B EV / Sales 2026 *
-
EV / Sales 2027 * 7.31x
Free-Float
78.77%
Yield 2026 *
-
Yield 2027 * -
1 day-2.25%
1 week+3.17%
Current month+2.56%
1 month+12.77%
3 months+23.17%
6 months+12.04%
Current year+20.05%
1 week 5.02
Extreme 5.02
5.62
1 month 4.5
Extreme 4.5
5.62
Current year 4.01
Extreme 4.01
5.62
1 year 3.06
Extreme 3.06
5.62
3 years 2.3
Extreme 2.3
12.27
5 years 2.3
Extreme 2.3
289.2
10 years 2.3
Extreme 2.3
583.5
Manager TitleAgeSince
Chief Executive Officer 52 01/07/2022
Director of Finance/CFO 39 -
Chief Tech/Sci/R&D Officer 61 18/08/2025
Director TitleAgeSince
Director/Board Member 84 01/04/2008
Director/Board Member 52 08/08/2022
Director/Board Member 74 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
03-18Other

Director

21,565 0.1130%
03-18Other

Chief Operating Officer

159,394 0.8353%
03-18Other

Director

24,623 0.1290%
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%+3.17%+51.90%-57.42% 99.9M
-1.60%+2.02%+56.34%+168.94% 1,084B
-1.44%+3.71%+69.07%+65.40% 634B
-0.75%+0.67%+33.18%+86.52% 447B
-0.36%-2.14%+28.54%+25.99% 330B
-8.55%-10.40%+25.71%+27.96% 295B
-0.64%-2.05%+28.55%+46.19% 285B
-1.08%-3.61%-27.77%-39.72% 218B
-0.03%+1.84%+23.90%+68.30% 199B
-0.40%+7.82%+22.29%+82.50% 169B
Average -1.38%+2.59%+31.17%+47.47% 366B
Weighted average by Cap. -0.84%+2.48%+40.24%+85.26%

Financials

2026 *2027 *
Net sales - 13.68M 11.99M 11.07M 10.23M 19.4M 1.31B 19.78M 133M 51.72M 641M 51.35M 50.23M 2.22B
Net income -33.91M -29.74M -27.46M -25.38M -48.1M -3.25B -49.06M -330M -128M -1.59B -127M -125M -5.52B -32.76M -28.73M -26.53M -24.51M -46.46M -3.14B -47.39M -319M -124M -1.54B -123M -120M -5.33B
Net Debt - -
Logo PolyPid Ltd.
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Employees
72
Date Price Change Volume
08/07/26 $5.210 -2.25% 270,008
07/07/26 $5.330 -4.48% 189,764
06/07/26 $5.580 +11.16% 504,200
02/07/26 $5.020 -0.59% 223,851
01/07/26 $5.050 -0.59% 188,608
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.210USD
Average target price
12.25USD
Spread / Average Target
+135.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYPD Stock